This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
20 Feb 2012

Par Pharmaceutical Completes Acquisition of Edict Pharmaceuticals

Par Pharmaceutical has completed the acquisition of India-based Edict Pharmaceuticals, a developer and manufacturer of generic pharmaceuticals with 11 ANDAs filed with the FDA.

US-based specialty pharmaceutical company Par Pharmaceutical has completed the acquisition of Edict Pharmaceuticals Private Limited, an India-based developer and manufacturer of generic pharmaceuticals.

 

Par paid $20.5 million at closing and $4.4 million repayment of certain pre-close indebtedness.

 

Edict is a Chennai, India-based developer and manufacturer of solid oral dosage generic pharmaceuticals with a highly-skilled research and development team and strong product pipeline focused on niche first-to-file, first-to-market products. Edict currently has 11 ANDAs filed with the U.S. FDA.

 

In connection with the closing of the acquisition, the previously-disclosed

Related News